ID

16688

Beschrijving

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of Study: Study Drug Administration

Link

https://clinicaltrials.gov/ct2/show/NCT00373425

Trefwoorden

Versies (2)
  1. 27-07-16 27-07-16 -
  2. 01-08-16 01-08-16 -
Geüploaded op

1 augustus 2016

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425

Engels

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 Formulieren  
Study Drug Administration
Beschrijving

Study Drug Administration

Start Date
Beschrijving

Study Drug Administration Start Date

Datatype

date

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0808070
Administered Dose
Beschrijving

Dose

Datatype

float

Maateenheden
  • mg
Alias
UMLS CUI [1]
C0178602
mg
Stop Date
Beschrijving

Study Drug Administration Stop Date

Datatype

date

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0806020
Dose Modification
Beschrijving

Record toxicities on the Adverse Events page.

Datatype

integer

Alias
UMLS CUI [1,1]
C1707811
UMLS CUI [1,2]
C0392360
If other, specify:
Beschrijving

Other Dose Modification Reason

Datatype

text

Alias
UMLS CUI [1,1]
C1707811
UMLS CUI [1,2]
C3840932
Missed Doses
Beschrijving

Record the number of missed doses, if any, for the time between the start and stop dates.

Datatype

integer

Alias
UMLS CUI [1,1]
C1709043
UMLS CUI [1,2]
C0750480
Terug naar het begin van de pagina

Similar models

Study Drug Administration, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
Study Drug Administration
Study Drug Administration Start Date
Item
Start Date
date
C0013227 (UMLS CUI [1,1])
C0808070 (UMLS CUI [1,2])
Dose
Item
Administered Dose
float
C0178602 (UMLS CUI [1])
Study Drug Administration Stop Date
Item
Stop Date
date
C0013227 (UMLS CUI [1,1])
C0806020 (UMLS CUI [1,2])
Item
Dose Modification
integer
C1707811 (UMLS CUI [1,1])
C0392360 (UMLS CUI [1,2])
Study Drug Dose Modification
Code List
Dose Modification
CL Item
Drug-related Toxicity (AE) (1)
CL Item
Nondrug-related Toxicity (AE) (2)
CL Item
Patient Request  (3)
CL Item
Toxicity lmproved  (4)
CL Item
No Modification (5)
CL Item
Other (specify) (6)
Other Dose Modification Reason
Item
If other, specify:
text
C1707811 (UMLS CUI [1,1])
C3840932 (UMLS CUI [1,2])
Missed Doses
Item
Missed Doses
integer
C1709043 (UMLS CUI [1,1])
C0750480 (UMLS CUI [1,2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial